Standout Papers

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Periphe... 2012 2026 2016 2021 472
  1. Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy (2012)
    Bertrand Coiffier, Barbara Pro et al. Journal of Clinical Oncology

Immediate Impact

2 from Science/Nature 55 standout
Sub-graph 1 of 22

Citing Papers

Advances in targeting histone deacetylase for treatment of solid tumors
2024 Standout
Transient loss of Polycomb components induces an epigenetic cancer fate
2024 StandoutNature
11 intermediate papers

Works of Barbara Balser being referenced

Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials
2017
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
2012 Standout
and 2 more

Author Peers

Author Last Decade Papers Cites
Barbara Balser 341 344 269 450 14 775
Shanta Chawla 311 277 197 327 15 671
Anagh A. Sahasrabuddhe 513 213 219 254 22 908
Christiane Dimmler 299 363 141 331 12 754
Larisa J. Geskin 424 182 164 197 16 666
J-Y Chen 378 490 166 330 12 904
Lippman Sm 339 215 160 322 15 792
Karsten W. Eriksen 144 215 368 156 15 679
Christine Brender 255 441 468 167 12 863
TW Mak 143 197 292 290 13 668
RA Miller 168 241 346 335 12 790

All Works

Loading papers...

Rankless by CCL
2026